Exact Sciences logo
United States
Choose your country

Select to view the solutions available in your location.

Select
Cancel
Login
Patient login

Track orders, get results, manage personal information, and more.

Provider login

Order tests, track orders, get results, and more.

ENABLING THE NEXT ERA OF INFORMED CANCER CARE.

alt text for all sources

THE 2025 ANNUAL MEETING

BOOTH #21131 | CHICAGO, ILLINOIS | MAY 30-JUNE 3​

You have come to depend on Exact Sciences for our trusted portfolio of solutions, including the Oncotype DX®, OncoExTra®, Cologuard® brand tests, and Riskguard® test.

Now it’s time to discover the latest addition to our portfolio: the NEW Oncodetect™ Molecular Residual Disease (MRD) test.

VISIT BOOTH #21131 AT THE 2025 ASCO® ANNUAL MEETING to discover how our new MRD test can enable critical decisions regarding adjuvant therapy, cancer recurrence, and your patient’s response to treatment.

The Oncodetect™ Test

Treatment Insights

Early Detection

Innovation

The Oncodetect™ Test

MRD can be hard to find. The Oncodetect™ test makes it hard to miss.

LEARN MORE

INTRODUCING A NEW MRD TEST FOR SOLID TUMORS

oncodetect Logo

Uncover elusive circulating tumor DNA (ctDNA) in the sea of cell-free DNA.
By detecting even slight amounts of ctDNA, the Oncodetect™ test can identify MRD that lingers beneath the detection threshold of standard of care surveillance.1,2

The Oncodetect test meticulously tracks up to 200 variants specific to the patient’s tumor for more opportunities to detect ctDNA in the blood.1,3​

This tumor-informed test can also:

  • Uncover ctDNA with high sensitivity and specificity1
  • Provide a low limit of detection of 0.005% tumor fraction
  • Detect signs of cancer recurrence more than 2 years earlier than imaging4

    • The Oncodetect test can deliver deeper insights into cancer care at multiple phases throughout the treatment journey, including post-surgery, recurrence monitoring, and response to treatment.1





    References:
    1. Diergaarde B, Young G, Hall DW, et al. Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: the α-CORRECT study. J Surg Oncol. Jan 2025. doi: 10.1002/jso.27989.
    2. Chakrabarti S, Kasi AK, Parikh AR, et al. Finding Waldo: the evolving paradigm of circulating tumor DNA (ctDNA)–guided minimal residual disease (MRD) assessment in colorectal cancer (CRC). Cancers. 2022;14:3078.
    3. Santonja A, Cooper W, Eldridge M, et al. Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer. EMBO Mol Med. 2023;15(6):e16505.
    4. Diergaarde B, Young G, Hall DW, et al. Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: the α-CORRECT study. J Surg Oncol. Jan 2025. (Suppl). doi: 10.1002/jso.27989

    Treatment insights

    Make pivotal cancer treatment decisions with timely, actionable insights. Our diverse portfolio of genomic and genetic tests provides personalized guidance at key moments, spanning from risk assessment and prognosis to recurrence monitoring and therapy selection for advanced-stage cancer.

    LEARN MORE

    PREDICTING CHEMOTHERAPY BENEFIT IN EARLY-STAGE HR+, HER2- BREAST CANCER

    Oncotype Dx logo

    The Oncotype DX Breast Recurrence Score® test is the only genomic test proven to predict a patient’s individual benefit from chemotherapy.1,2

    HEREDITARY CANCER RISK ASSESSMENT

    Riskguard logo

    The Riskguard® test is a 56-gene risk assessment tool that identifies hereditary genetic changes that may impact clinical decision-making in breast, ovarian, prostate, endometrial, colorectal, pancreatic, gastric, kidney, endocrine, and skin cancers. (Not available in all countries.)

    ADVANCED CANCER TREATMENT SELECTION

     

    The OncoExTra test is an ultra-comprehensive genomic test that uses DNA and RNA to identify clinically actionable alterations and any associated therapies or clinical trials—delivering your patient’s complete genomic story in one streamlined report. (Not available in all countries.)

    References: 
     1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
    2. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.

    Early detection

    The first step in changing the way we treat cancer? Detecting it earlier. Our screening tests can deliver earlier answers to help drive care decisions. Not available outside the United States.

    LEARN MORE

    THE NON-INVASIVE mt-sDNA TEST

    Cologuard logo

    A noninvasive, FDA-approved colorectal cancer screening test that looks for multiple abnormal biomarkers, including DNA and blood in stool, the Cologuard® (multi-target stool DNA [mt-sDNA]) test finds colon cancer even in early stages when it is more effective.1-3* Not available outside the United States. For adults 45+ at average risk. Rx only.

    COLOGUARD PLUS

    Cologuard Plus logo

    The new version of the colorectal cancer screening test builds on the success of the Cologuard® test and leverages 10 years of innovation and experience to improve performance without losing ease of use or convenience. Not available outside the United States. For adults 45+ at average risk. Rx only.

    EARLY-STAGE LIVER CANCER DETECTION

    Oncoguard® Liver logo.

    A sophisticated, yet simple, single blood test, the Oncoguard® Liver solution delivers advanced sensitivity and specificity to aid consistent and reliable hepatocellular cancer detection. Not available outside the United States.

    *Based on 5-year relative survival.


    References:
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
    2. Cologuard Clinician Brochure. Exact Sciences Corporation. Madison, WI.
    3. American Cancer Society. Survival rates for colorectal cancer. Accessed April 4, 2024. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html

    Innovation

    The future depends on today’s accomplishments. Our team of innovators is constantly working to develop life-changing solutions in cancer screening and genomic testing.

    LEARN MORE

    COLORECTAL CANCER SCREENING

    Multi-Target CRC Blood Test

    To provide more options for the approximately 60 million average-risk Americans aged 45 to 85 years who remain unscreened, Exact Sciences is developing a blood-based screening method for colorectal cancer to give you and your patients more choices.1

    MULTI-CANCER EARLY DETECTION

    Cancerguard™ Logo.

    Only one-third of diagnosed cancers have routine recommended screening tests.2* Many more cancers may go undetected until they are more advanced.3 The Cancerguard™ test in development is being designed to detect multiple cancers, even in their earliest stages, from a single blood draw.3 When used alongside single-organ standard-of-care cancer screenings, such as breast and colorectal cancer screenings, multi-cancer early detection (MCED) tests may offer the potential to transform the way we screen for cancer.

    Cancerguard™ Logo.

    For information about the multi-cancer early detection test currently available--- The Cancerguard EX test, contact us here.

    *Calculated using estimated new diagnoses and deaths from cancers that have standard of care screening: breast, cervical, colorectal, and lung (high-risk) against all sites

    The technologies in this section are under development. The features described are current development goals. They have not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.

    References:
    1. Ebner DW, Kisiel JB, Fendrick AM, et al. Estimated average-risk colorectal cancer screening-eligible population in the US. JAMA Netw Open. 2024;7(3):e245537.
    2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
    3. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.

    ATTEND OUR JUNE 1st
    INDUSTRY EXPERT THEATER

    MOLECULAR RESIDUAL DISEASE TESTING WITH EXACT SCIENCES’ ONCODETECT™ TEST: PRODUCT AND CLINICAL DATA OVERVIEW

    Get introduced to Exact Sciences’ Oncodetect molecular residual disease (MRD) test. Learn about the test, its approach to detecting MRD in solid tumors, and its clinical validation results in colorectal cancer.

    Speakers:
    Rick Baehner, MD

    Rick Baehner, MD
    Chief Medical Officer of Precision Oncology, Exact Sciences

    Somasundaram Subramaniam, MD, MS Somasundaram Subramaniam, MD, MS
    Director, Medical Development, Exact Sciences

    Sunday, June 1 | 9:30 AM – 10:30 AM
    Exhibit Hall, Industry Expert Theater 2



    Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

    Abstracts of interest

    Light bulb icon.

    The Association of Circulating Tumor DNA (ctDNA) with Recurrence in Patients with Stage II-IV Colorectal Cancer: The ꞵ-CORRECT Study

    Authors

    Tadayoshi Hashimoto, Yoshiaki Nakamura, Gregory Young, Melanie Palomares, Somasundaram Subramaniam, David Hall, Judith Frederick, Eiji Oki, Daisuke Kotani, Saori Mishima, Jun Watanabe, Naoya Akazawa, Kozo Kataoka, Hideaki Bando, Takeshi Kato, Gina Costa, Amin Mazloom, Frederick Baehner, Takayuki Yoshino, Jorge Garces

    Abstract Number

    3590

    Light bulb icon.

    Molecular Residual Disease (MRD) in Solid Tumors

    Authors

    Majd Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-Macinnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Somasundaram Subramaniam, Anthony Tate, Kathleen Turnbull, Neal Meropol

    Abstract Number

    TPS3186

    Light bulb icon.

    Enhancing Recurrence Detection in Stage III Colorectal Cancer Patients Through Molecular Residual Disease Test-guided Surveillance: A Modeling Study 

    Authors

    Sumeyye Samur, Emir Gursel, Ning Gu, Gebra Cuyun Carter, Mert Sahinkoc, Turgay Ayer, Jagpreet Chhatwal, Rod Tavallai, Somasundaram Subramaniam, Melanie Palomares, Aparna Parikh, Rick Baehner, Alfred Neugut

    Abstract Number

    e15600

    VIEW ALL